Epitope specificities of broadly neutralizing plasmas from HIV-1 infected subjects

Vaccine

Volumn 28, Issue SUPPL. 2, 2010, Pages

  Sather, D Noah ^a   Stamatatos, Leonidas ^a,b  

^a SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Broadly cross neutralizing plasma; Epitope specificities; HIV 1; Neutralizing antibodies

Indexed keywords

EPITOPE; GLYCOPROTEIN GP 41; MONOCLONAL ANTIBODY 4E10; NEUTRALIZING ANTIBODY;

ADSORPTION; ANTIBODY RESPONSE; ARTICLE; BINDING SITE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CROSS REACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; NONHUMAN; PRIORITY JOURNAL; VIRUS NEUTRALIZATION;

ANTIBODIES, NEUTRALIZING; ANTIBODY SPECIFICITY; COHORT STUDIES; CROSS REACTIONS; EPITOPES; FEMALE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; MALE; NEUTRALIZATION TESTS;

EID: 77952516203     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.07.085     Document Type: Article

References (26)

1. Hu S.L., and Stamatatos L. Prospects of HIV Env modification as an approach to HIV vaccine design. Current HIV Res 5 6 (2007) 507-513
2. Brown B.K., Wieczorek L., Sanders-Buell E., Borges A.R., Robb M.L., Birx D.L., et al. Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models. Virology 375 2 (2008 Jun 5) 529-538
3. Kostrikis L.G., Cao Y., Ngai H., Moore J.P., and Ho D.D. Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement. J Virol 70 1 (1996) 445-458
4. Moore J.P., Cao Y., Leu J., Qin L., Korber B., and Ho D.D. Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. J Virol 70 1 (1996) 427-444
5. Tomaras G.D., Yates N.L., Liu P., Qin L., Fouda G.G., Chavez L.L., et al. Initial B cell responses to transmitted HIV-1: virion-binding IgM and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol (2008 Oct 8)
6. Richman P., Wrin T., Little S.J., and Petropoulos C.J. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proceedings of the National Academy of Sciences of the United States of America 100 April (7) (2003) 4144-4149
7. Sather D.N., Armann J., Ching L.K., Mavrantoni A., Sellhorn G., Caldwell Z., et al. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol 83 2 (2009) 757-769
8. Montefiori D.C. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr Protoc Immunol January (2005) [chapter 12:unit 12.1]
9. Derby N.R., Kraft Z., Kan E., Crooks E.T., Barnett S.W., Srivastava I.K., et al. Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection. J Virol 80 17 (2006) 8745-8762
10. Saunders C.J., McCaffrey R.A., Zharkikh I., Kraft Z., Malenbaum S.E., Burke B., et al. The V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner. J Virol 79 14 (2005) 9069-9080
11. Li M., Gao F., Mascola J.R., Stamatatos L., Polonis V.R., Koutsoukos M., et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 79 16 (2005) 10108-10125
12. Li Y., Migueles S.A., Welcher B., Svehla K., Phogat A., Louder M.K., et al. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nature Med 13 9 (2007) 1032-1034
13. Doria-Rose N.A., Klein R.M., Manion M.M., O'Dell S., Phogat A., Chakrabarti B., et al. Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J Virol 83 1 (2009) 188-199
14. Binley J.M., Lybarger E.A., Crooks E.T., Seaman M.S., Gray E., Davis K.L., et al. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol 82 23 (2008) 11651-11668
15. Li Y., Svehla K., Louder M.K., Wycuff D., Phogat S., Tang M., et al. Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J Virol 83 2 (2009) 1045-1059
16. Davis K.L., Bibollet-Ruche F., Li H., Decker J.M., Kutsch O., Morris L., et al. Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma. J Virol 83 3 (2009) 1240-1259
17. Davis K.L., Gray E.S., Moore P.L., Decker J.M., Salomon A., Montefiori D.C., et al. High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination. Virology 387 2 (2009 May 10) 414-426
18. Dhillon A.K., Donners H., Pantophlet R., Johnson W.E., Decker J.M., Shaw G.M., et al. Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J Virol 81 12 (2007) 6548-6562
19. Nelson J.D., Brunel F.M., Jensen R., Crooks E.T., Cardoso R.M., Wang M., et al. An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10. J Virol 81 8 (2007) 4033-4043
20. Zwick M.B. The membrane-proximal external region of HIV-1 gp41: a vaccine target worth exploring. AIDS (London, England) 19 November (16) (2005) 1725-1737
21. Parker C.E., Deterding L.J., Hager-Braun C., Binley J.M., Schulke N., Katinger H., et al. Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5. J Virol 75 22 (2001) 10906-10911
22. Binley J.M., Wrin T., Korber B., Zwick M.B., Wang M., Chappey C., et al. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol 78 23 (2004) 13232-13252
23. Shen X., Parks R.J., Montefiori D.C., Kirchherr J.L., Keele B.F., Decker J.M., et al. In Vivo gp41 Antibodies Targeting the 2F5 mAb Epitope Mediate HIV-1 Neutralization Breadth. J Virol 83 8 (2009) 3617-3625
24. Moore J.P., Cao Y., Ho D.D., and Koup R.A. Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1. J Virol 68 8 (1994) 5142-5155
25. Burton D.R., Pyati J., Koduri R., Sharp S.J., Thornton G.B., Parren P.W., et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science New York, NY 266 November (5187) (1994) 1024-1027
26. Roben P., Moore J.P., Thali M., Sodroski J., Barbas C.F.3r., and Burton D.R. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J Virol 68 8 (1994) 4821-4828